{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:56:33Z","timestamp":1791327393792,"version":"4.3.1"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T00:00:00Z","timestamp":1433721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"NCI Intramural Program"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2015,10]]},"abstract":"\n Objective<\/jats:title>\n \n TRC<\/jats:styled-content>\n 105 is a chimeric immunoglobulin\n G<\/jats:styled-content>\n 1 monoclonal antibody that binds endoglin (\n CD<\/jats:styled-content>\n 105). This phase\n I<\/jats:styled-content>\n open\u2010label study evaluated the safety, pharmacokinetics and pharmacodynamics of\n TRC<\/jats:styled-content>\n 105 in patients with metastatic castration\u2010resistant prostate cancer (\n mCRPC<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n Patients with\n mCRPC<\/jats:styled-content>\n received escalating doses of i.v.\n TRC<\/jats:styled-content>\n 105 until unacceptable toxicity or disease progression, up to a predetermined dose level, using a standard 3 + 3 phase\n I<\/jats:styled-content>\n design.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 20 patients were treated. The top dose level studied, 20\u2009mg\/kg every 2 weeks, was the maximum tolerated dose. Common adverse effects included infusion\u2010related reaction (90%), low grade headache (67%), anaemia (48%), epistaxis (43%) and fever (43%). Ten patients had stable disease on study and eight patients had declines in prostate specific antigen (PSA). Significant plasma\n CD<\/jats:styled-content>\n 105 reduction was observed at the higher dose levels. In an exploratory analysis, vascular endothelial growth factor (\n VEGF<\/jats:styled-content>\n ) was increased after treatment with\n TRC<\/jats:styled-content>\n 105 and\n VEGF<\/jats:styled-content>\n levels were associated with\n CD<\/jats:styled-content>\n 105 reduction.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n TRC<\/jats:styled-content>\n 105 was tolerated at 20\u2009mg\/kg every other week with a safety profile distinct from that of\n VEGF<\/jats:styled-content>\n inhibitors. A significant induction of plasma\n VEGF<\/jats:styled-content>\n was associated with\n CD<\/jats:styled-content>\n 105 reduction, suggesting anti\u2010angiogenic activity of\n TRC<\/jats:styled-content>\n 105. An exploratory analysis showed a tentative correlation between the reduction of\n CD<\/jats:styled-content>\n 105 and a decrease in\n PSA<\/jats:styled-content>\n velocity, suggestive of potential activity of\n TRC<\/jats:styled-content>\n 105 in the patients with\n mCRPC<\/jats:styled-content>\n . The data from this exploratory analysis suggest that rising\n VEGF<\/jats:styled-content>\n level is a possible compensatory mechanism for\n TRC<\/jats:styled-content>\n 105\u2010induced anti\u2010angiogenic activity.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.12986","type":"journal-article","created":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T02:38:19Z","timestamp":1416364699000},"page":"546-555","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["A phase\n I<\/scp>\n study of\n TRC<\/scp>\n 105 anti\u2010endoglin (\n CD<\/scp>\n 105) antibody in metastatic castration\u2010resistant prostate cancer"],"prefix":"10.1111","volume":"116","author":[{"given":"Fatima H.","family":"Karzai","sequence":"first","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Apolo","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cao","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Adelberg","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Parnes","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"McLeod","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Harold","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Peer","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunkai","family":"Yu","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tomita","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min\u2010Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunmin","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane B.","family":"Trepel","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Dahut","sequence":"additional","affiliation":[{"name":"Medical Oncology Service National Cancer Institute Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21166"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903451716"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/361836"},{"key":"e_1_2_6_7_1","first-page":"401","article-title":"Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma","volume":"143","author":"Weidner N","year":"1993","journal-title":"Am J Pathol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70239-0"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.4767"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70184-0"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5268"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720111793663570"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050920"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5419.1534"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0098"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-2-18","article-title":"Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer","volume":"2","author":"Fonsatti E","year":"2004","journal-title":"J Transl Med"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4478"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0634rev"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10083"},{"key":"e_1_2_6_20_1","first-page":"4221","article-title":"Differential vascular and transcriptional responses to anti\u2010vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts","volume":"9","author":"Bockhorn M","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-2879-2"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2665"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.05.016"},{"key":"e_1_2_6_24_1","unstructured":"RosenLS GordonMS HurwitzHIet\u2009al.Phase 1 Study of TRC105 [Anti\u2010CD105 (Endoglin) Antibody] Therapy in Patients with Advanced Refractory Cancer.2009Available at:http:\/\/www.traconpharma.com\/pdfs\/105ST101_ASCO2009Electronic%20Submission.pdf. Accessed June 2014"},{"key":"e_1_2_6_25_1","first-page":"7846","article-title":"Antiangiogenic therapy of established tumors in human skin\/severe combined immunodeficiency mouse chimeras by anti\u2010endoglin (CD105) monoclonal antibodies, and synergy between anti\u2010endoglin antibody and cyclophosphamide","volume":"61","author":"Takahashi N","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_26_1","unstructured":"A Phase I\/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC). Available at:http:\/\/clinicaltrials.gov\/show\/NCT01090765. Accessed June 2014"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12311"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132577"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0310"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2013.855194"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3291"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3333"},{"key":"e_1_2_6_35_1","first-page":"393","article-title":"Beyond anti\u2010VEGF: dual\u2010targeting antiangiogenic and antiproliferative therapy","volume":"5","author":"Chen CT","year":"2013","journal-title":"Am J Transl Res"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31827e0b86"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4524"},{"key":"e_1_2_6_38_1","unstructured":"A Phase 2 Trial of Bevacizumab Lenalidomide Docetaxel and Prednisone (ART\u2010P) for Treatment of Metastatic Castrate\u2010Resistant Prostate Cancer. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00942578?=NCT00942578&rank=1. Accessed June 2014"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2812"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1143"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12986","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:57:17Z","timestamp":1761757037000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,8]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/bju.12986"],"URL":"https:\/\/doi.org\/10.1111\/bju.12986","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,8]]},"assertion":[{"value":"2015-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}